Form 4 for FBIO Fortress Biotech, Inc.
Accepted 2023-01-04 00:00:00 ET · period of report 2023-01-01 · accession 0001104659-23-001095 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-04 | 2023-01-01 | FBIO | Hoenlein Malcolm | Dir | A - Grant | $0.00 | +50.0K | 535.6K | +10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK, PAR VALUE $0.001 | 2023-01-01 | A | A | 50,000 | $0.00 | 535,636 | D | — | — | (F1) One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer. (F2) The total holdings include 450,000 shares underlying deferred restricted stock units. |